• About
  • About CANNT
  • Major Activities
  • Board of Directors and Contacts
    • News from the President
  • Current Bylaws
  • Why should I become a member?
    • Fact Sheet on Representation
    • Fact Sheet on Liaisons
  • Join CANNT
• CANNT Journal
  • CANNT Journal
    • 2011
    • 2010
    • 2009
    • 2008
    • 2007
    • 2006
    • 2005
    • 2003
    • 2002
    • 2004
    • 2001
    • 2000
  • Download Journals
  • Information for Advertisers
  • Guidelines For Authors
  • Library/Institutional Rates
• Standards of Practice
  • Standards of Nursing Practice
  • Standards of Technical Practice
• Events
  • Calendar
  • CANNT 2011
    • PowerPoints and Handouts
  • CANNT 2012
• Education
  • Certification
  • CNeph(C) Prep Course
  • CEU Tests
  • ABSTRACTS 101 - Workshop Materials
  • CKD Best Practice Guidelines
  • Poster Preparation and Judging Guidelines
• Resources
  • Career Opportunities (Last posting: November 29, 2011)
    • Advertisers
  • CANNT Awards, Bursaries & Grants
    • CANNT Bursaries & Grants
    • Excellence in Practice Awards
  • Amgen Canada Travel, Research & Preceptorship/Mentorship Grants Program
    • Grant Review Committee Assessment Guide
  • Internet Links
• Members
  • Renew Membership
  • Change Contact Info
  • Discussion Forum
  • Refined Clinical Practice Groups (RCPGs)
    • RALNO
    • CHAC
    • Canadian Nephrology Nurse Practitioners (CNNP)
    • Home Dialysis Interest Group
  • CEU Tests
    • Purchase CEU Tokens
  • Change Password
  • Regional Reports
    • Western Region
    • Ontario
    • Quebec
    • Atlantic
    • Technical
  • Award Winners
  • Educational Opportunities
  • CKD Review Modules
  • My Profile

20_1_4

After reading the article, the reader will be able to:

• Define the term chronic kidney disease-mineral and bone disorders (CKD-MBD), as outlined by Kidney Disease:

Improving Global Outcomes (KDIGO)

• Describe how patients develop CKD-MBD, and the potential complications of untreated CKD-MBD

• Define the frequency of monitoring and recommended targets laboratory parameters associated with CKD-MBD

• Compare and contrast currently available agents to treat elevated serum phosphorus and parathyroid hormone

associated with CKD-MBD.